Clinical trials: Severe Hypertriglyceridemia, open to volunteers
Severe Hypertriglyceridemia
A Phase 3 Trial of DR10624 Versus Placebo in Patients With Severe Hypertriglyceridemia
This is a multicenter, randomized, double-blind, placebo-controlled Phase 3 trial for adults with severe hypertriglyceridemia whose lipid levels remain uncontrolled under standard Icosapent Ethyl background treatment plus…
- Trial name
- NCT07680829
- Testing
- DR10624 Subcutaneous Injection, Icosapent Ethyl Oral Capsule
- Where
- 2 sites in China
- Volunteers
- 378 people
- Sponsor
- Zhejiang Doer Biologics Co., Ltd.
Familial Chylomicronemia Syndrome (FCS)
CS-121 APOC3 Base Editing in FCS
This is an open-label, single-arm, dose-escalation Phase I clinical trial to evaluate the safety, tolerability, pharmacodynamics (PD), and pharmacokinetics (PK) of CS-121, an in vivo base editing therapy delivered by lipid…
- Trial name
- NCT07176923
- Testing
- CS-121
- Where
- China
- Volunteers
- 15 people
- Sponsor
- CorrectSequence Therapeutics Co., Ltd
Severe Hypertriglyceridemia
A Study of Solbinsiran (LY3561774) in Participants With Severe Hypertriglyceridemia
The purpose of this study is to evaluate the safety and efficacy of solbinsiran in lowering triglycerides and other lipid measures compared to placebo in participants with severe hypertriglyceridemia.
- Trial name
- SOLARIS-1 (NCT07269210)
- Testing
- Solbinsiran
- Where
- 41 sites in United States, Canada and 2 more
- Volunteers
- 60 people
- Sponsor
- Eli Lilly and Company
Severe Hypertriglyceridemia
Study of Plozasiran in Adults With Severe Hypertriglyceridemia at Risk of Acute Pancreatitis
This study will evaluate the efficacy and safety of plozasiran in approximately 288 adult participants with severe hypertriglyceridemia (SHTG) and history of at least two prior acute pancreatitis (AP) events not attributed to…
- Trial name
- SHASTA-5 (NCT06880770)
- Testing
- Plozasiran
- Where
- 140 sites in United States, Argentina and 25 more
- Volunteers
- 288 people
- Sponsor
- Arrowhead Pharmaceuticals
Hypertriglyceridemia, Severe Hypertriglyceridemia
A Study to Assess the Safety, Tolerability and Efficacy of ION775
The main objective of this study is to evaluate the effect of ION775 on fasting triglyceride (TG) levels in participants with hypertriglyceridemia (HTG) and severe hypertriglyceridemia (sHTG).
- Trial name
- NCT07604974
- Testing
- ION775
- Where
- 18 sites in United States, Canada
- Volunteers
- 72 people
- Sponsor
- Ionis Pharmaceuticals, Inc.
sHTG, HTG With ASCVD (Diagnosed or at Increased Risk)
A Phase II Study of FXR0906 in Patients With Severe Hypertriglyceridemia or Hypertriglyceridemia With ASCVD.
This is a multicenter, randomized, double-blind, placebo-controlled, phase II clinical trial evaluating the efficacy and safety of FXR0906 in patients with severe hypertriglyceridemia or hypertriglyceridemia with atherosclerotic…
- Trial name
- NCT07889245
- Testing
- FXR0906 injection
- Where
- China
- Volunteers
- 192 people
- Sponsor
- Fosun Pharmaceutical Industrial Development (Shenzhen) Co., Ltd.
Severe Hypertriglyceridemia (sHTG)
CS-121 APOC3 Base Editing in Severe Hypertriglyceridemia
This is an open-label, single-arm, dose-escalation IIT clinical trial to evaluate the safety, tolerability, pharmacodynamics (PD), and pharmacokinetics (PK) of CS-121, an in vivo base editing therapy delivered by lipid…
- Trial name
- NCT07657780
- Testing
- CS-121
- Where
- China
- Volunteers
- 15 people
- Sponsor
- CorrectSequence Therapeutics Co., Ltd
Severe Hypertriglyceridemia (sHTG), Hypertriglyceridemia
A Phase III Study to Evaluate the Efficacy and Safety of of DR10624 in Subjects With Severe Hypertriglyceridemia
This is a multicenter, randomized, double-blind, placebo-controlled Phase 3 clinical trial to assess the efficacy and safety of weekly subcutaneous DR10624 injection in adult patients with severe hypertriglyceridemia (sHTG).
- Trial name
- NCT07693777
- Testing
- DR10624 Injection
- Where
- China
- Volunteers
- 480 people
- Sponsor
- Zhejiang Doer Biologics Co., Ltd.
Cardiovascular, Metabolic Disease
A Safety and Tolerability Trial Evaluating CTX310 in Participants With Refractory Dyslipidemias
This is a single-arm, open-label, multicenter, ascending dose Phase 1 trial that will enroll participants 18 to 75 years of age with dyslipidemias that are refractory to available treatments.
- Conditions
- Cardiovascular, Metabolic Disease, Dyslipidemias, Lipid Disorder
- Trial name
- NCT07491172
- Testing
- CTX310
- Where
- 17 sites in United States, Australia and 2 more
- Volunteers
- 90 people
- Sponsor
- CRISPR Therapeutics AG
Lipodystrophy (Genetic or Acquired, Non HIV)
The LD Lync Study - Natural History Study of Lipodystrophy Syndromes
Genetic lipodystrophy syndromes are extremely rare, orphan diseases with overall estimated prevalence of less than 2,000 in the United States.
- Trial name
- NCT03087253
- Where
- 4 sites in United States, Brazil and 1 more
- Volunteers
- 500 people
- Sponsor
- University of Michigan